<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380066</url>
  </required_header>
  <id_info>
    <org_study_id>AYPB-MDD-Ⅱa-1401</org_study_id>
    <secondary_id>2012ZX09303-003</secondary_id>
    <nct_id>NCT02380066</nct_id>
  </id_info>
  <brief_title>Comparison of Anyu Peibo With Placebo in Treatment of MDD</brief_title>
  <official_title>Proof Of Concept Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Su Zhou YiHua Biotechnology Co. LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Anyu Peibo Capsule in different doses are
      effective in the treatment of Depression.

      And to explore the preliminary information of safety and efficacy of Anyu Peibo Capsule in
      the Chinese Patients with Depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of total score from baseline in MADRS scale</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response rate according to MADRS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical remission rate according to MADRS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI(CGI-S,CGI-I)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total score from baseline in HAMD scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decreasing rate from baseline in HAMD scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response rate according to HAMD</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical remission rate according to HAMD</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in HAMA</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>vital sign</measure>
    <time_frame>6 weeks</time_frame>
    <description>Blood pressure, heart rate, temperature and respiratory rate</description>
  </other_outcome>
  <other_outcome>
    <measure>AE(adverse events)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>laboratory examination</measure>
    <time_frame>6 weeks</time_frame>
    <description>Blood RT, Urinalysis,Hepatic function,Renal function,FBG,Lipid,CK,HBV,Thyroid Function Test and U-HCG</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>C-SSRS</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Major Depressive Disorder (MDD)</condition>
  <arm_group>
    <arm_group_label>Anyu Peibo 0.4g per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anyu Peibo Capsule, oral, 0.2g twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anyu Peibo 0.8g per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anyu Peibo Capsule, oral, 0.4g twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anyu Peibo 1.2g per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anyu Peibo Capsule, oral, 0.6g twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anyu Peibo 1.6g per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anyu Peibo Capsule, oral, 0.8g twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo,oral, twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anyu Peibo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Anyu Peibo 0.4g per day</arm_group_label>
    <arm_group_label>Anyu Peibo 0.8g per day</arm_group_label>
    <arm_group_label>Anyu Peibo 1.2g per day</arm_group_label>
    <arm_group_label>Anyu Peibo 1.6g per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria
             of DSM-IV-TR, single episode or recurrent episode, not accompanied with psychotic
             symptoms. Coding of diagnosis included: 296.21 MDD single episode, mild 296.22 MDD
             single episode, moderate 296.31 MDD recurrent episode, mild 296.32 MDD recurrent
             episode, moderate

          -  The total score of HAMD-17 is ≥18 and ≤24 in both screening visit and baseline visit.

          -  The subject understands and consents to takes part in this clinical trials. The
             subjects should sign informed consent.

        Exclusion Criteria:

          -  The subject has a significant risk of suicide according to the investigator's opinion
             or has a score ≥3 on item 3(suicide assessment) of the HAMD or has made a suicide
             attempt.

          -  The subject has a current DSM-Ⅳ-TR axisⅠpsychiatric diagnosis other than depression.

          -  When the HAMD17 score of baseline visit compares with the screening visit, the
             decreasing rate is ≥25%.

          -  Any unstable cardiovascular, hepatic, renal, endocrine(thyroid gland dysfunction),
             blood,or other medical disease.

          -  Had a history of seizure disorder,except infantile febrile convulsion.

          -  The subject has accepted psychosurgery or electroconvulsive therapy within 3months.

          -  With psychotic symptoms.

          -  The subject has a history of mania episode, including manic, mixed or rapid cycle
             attack.

          -  The subject has a current diagnosis or history of depression due to any other
             psychotic disorder or a general medical condition.

          -  The subject with refractory depressive disorder,i.e.the patients who used at least two
             different mechanisms antidepressants with adequate dosage and duration treatment still
             had no respond.

          -  Clinically significant electrocardiographic(ECG) abnormalities or abnormal laboratory
             values(eg. Hepatic function above 1.5 times of clinical toplimit, renal function or
             thyroid gland function index above toplimit, routine blood, fasting blood glucose
             value above or below 1.1 times of the upper limit of normal or in 1.1 times with the
             clinical significance of abnormality).

          -  The subject has a diagnosis of alcohol or other substance abuse or dependence at least
             1 years prior to the baseline visit.

          -  Known hypersensitivity to Big Leaf Ju, or at least to two kinds of drugs, or serious
             allergic physique.

          -  Women who were pregnant, breast-feeding, or planning to become pregnant during study.
             Men who have request to fertility during study period. The subject could not take safe
             and effective birth control measures.

          -  The subject could not take medication according to the doctor's advice. i.e. the
             compliance of the subject is poor.

          -  The subject uses antidepressant drug normally before 2 weeks of screening, and stops
             using psychotropic drug less than 7 half-life period (monoamine oxidase inhibitor more
             than 2 weeks, fluoxetine more than 1 month).

          -  The subject has participated in a drug clinical trial within 1 month before screening.

          -  The investigator think the subject is unsuitable to enrol in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang LI, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anhui province hospital of TCM</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guang'anmen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Sixth Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Huiai Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu province hospital of TCM</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuxi Mental Health Center</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214151</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>December 29, 2019</last_update_submitted>
  <last_update_submitted_qc>December 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

